Transaction · 0001822629-26-000004

Lalwani Nikhil

Lalwani Nikhil, PRES, CEO, reported a transaction classified as withholding at ANI PHARMACEUTICALS INC involving 11688.000000 shares for an estimated $896469.60. Reported holdings after the transaction were 368872.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FPRES, CEO
ANIPANI PHARMACEUTICALS INC
Filing timeFeb 17
Trade dateFeb 12, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$78.90
Pre-filing
1mo ago +4.3%1w ago +3.3%1d ago -3.4%
Returns since
7d -2.8%30d -5.2%90d +0.6%180d -3.0%1y -6.8%

ANIP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ANIP since 2026-02-17Filed 199 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0001822629-26-000004
Common Stock
Transaction date
Feb 12, 2026
Filed Feb 17, 2026, 12:00 AM · 5d delay
Shares
11.6k sh
$7.67k per share
Estimated value
-$89.6M
Computed from shares × price
Holdings after
368k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

PRESIDENT & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

  2. F2

    Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Original filing · 0001822629-26-000004
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ANIP